ghk-cu fda approval status injection adds non-injectable back to Category 1. FDA Thursday re-added non-injectable GHK-Cu to Category 1 of the 503A bulks process after the nomination was withdrawn from further review. Injectable GHK-Cu remains BPC-157 (CAS 137525-51-0) — firming and hydrating serum Style:NO LABEL

ghk-cu fda approval status injection adds non-injectable back to Category 1. FDA Thursday re-added non-injectable GHK-Cu to Category 1 of the 503A bulks process after the nomination was withdrawn from further review. Injectable GHK-Cu remains BPC-157 (CAS 137525-51-0) — firming and hydrating serum Style:NO LABEL

BPC-157 (CAS 137525-51-0) — Research Peptide, ≥99% HPLC | BNM Research Peptides

For any patient specific questions, consult your licensed pharmacist and prescribing clinician

firming and hydrating serum

Style:NO LABEL

Regulatory Status Compound FDA Status Availability CJC-1295 (No DAC) Not approved Research use only CJC-1295 (with DAC) Not approved Research use only Ipamorelin Not approved Research use only CJC-1295 + Ipamorelin Combo Not approved Research use only None of these compounds have received FDA approval for therapeutic use